Anika Therapeutics, Inc. (ANIK) Total liabilities 2016–2025
Anika Therapeutics, Inc. (ANIK) total liabilities at each fiscal year-end, per SEC filings.
$46.8MFY2025 · since FY2016: $17.5M → $46.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $46.8M | -4.0% |
| FY2024 | $48.8M | -16.5% |
| FY2023 | $58.4M | -8.2% |
| FY2022 | $63.6M | +5.2% |
| FY2021 | $60.5M | -35.1% |
| FY2020 | $93.2M | +120.2% |
| FY2019 | $42.3M | +175.2% |
| FY2018 | $15.4M | -19.6% |
| FY2017 | $19.1M | +9.5% |
| FY2016 | $17.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ANIK financial trends
ANIK RevenueANIK Net incomeANIK Net marginANIK Gross profitANIK Gross marginANIK Operating incomeANIK Operating marginANIK Operating cash flowANIK Free cash flowANIK Capital expendituresANIK Return on equityANIK Stock buybacksANIK Dividends paidANIK Total assetsANIK Shareholders’ equityANIK overview →